Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.
Inflamm Bowel Dis. 2012 Dec;18(12):2218-24. doi: 10.1002/ibd.22917. Epub 2012 Feb 16.
Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become a goal of treatment in IBD we examined how reliably calprotectin levels reflect mucosal disease activity.
In all, 126 IBD patients and 32 irritable bowel syndrome (IBS) patients needing colonoscopy delivered a sample of feces prior to the start of bowel cleansing. Besides collection of symptom scores and blood tests, experienced endoscopists recorded the Simple Endoscopic Score for Crohn's Disease (SES-CD) and the Crohn's Disease Endoscopic Index of Severity (CDEIS) in Crohn's disease (CD) patients and the Mayo endoscopic score in ulcerative colitis (UC) patients. Stool samples were shipped for central calprotectin PhiCal Assay (enzyme-linked immunosorbent assay [ELISA]). Correlation analysis was done with Pearson statistics.
The median (interquartile range [IQR]) fecal calprotectin levels were 175 (44-938) μg/g in CD, 465 (61-1128) μg/g in UC, and 54 (16-139) μg/g in IBS. Correlations were significant with endoscopic disease scores in both CD and in UC. Using ROC statistics, a cutoff value of 250 μg/g indicated the presence of large ulcers with a sensitivity of 60.4% and a specificity of 79.5% (positive predictive value [PPV] 78.4%, negative predictive value [NPV] 62.0%) in CD. Levels ≤ 250 μg/g predicted endoscopic remission (CDEIS ≤ 3) with 94.1% sensitivity and 62.2% specificity (PPV 48.5%, NPV 96.6%). In UC, a fecal calprotectin >250 μg/g gave a sensitivity of 71.0% and a specificity of 100.0% (PPV 100.0%, NPV 47.1%) for active mucosal disease activity (Mayo >0). Calprotectin levels significantly correlated with symptom scores in UC (r = 0.561, P < 0.001), but not in CD.
Fecal calprotectin levels correlate significantly with endoscopic disease activity in IBD. The test appears useful in clinical practice for assessment of endoscopic activity and remission.
粪便钙卫蛋白是炎症性肠病(IBD)炎症的标志物。由于黏膜愈合已成为 IBD 治疗的目标,我们研究了钙卫蛋白水平如何可靠地反映黏膜疾病活动度。
共有 126 例 IBD 患者和 32 例肠易激综合征(IBS)患者在开始肠道清洁前提供了粪便样本。除了收集症状评分和血液检查外,经验丰富的内镜医生还记录了克罗恩病简单内镜评分(SES-CD)和克罗恩病内镜严重程度指数(CDEIS)在克罗恩病(CD)患者和溃疡性结肠炎(UC)患者中的 Mayo 内镜评分。粪便样本用于中心钙卫蛋白 PhiCal 测定(酶联免疫吸附测定 [ELISA])。采用 Pearson 统计学进行相关分析。
CD 患者粪便钙卫蛋白中位数(四分位距 [IQR])为 175(44-938)μg/g,UC 患者为 465(61-1128)μg/g,IBS 患者为 54(16-139)μg/g。CD 和 UC 中,钙卫蛋白水平与内镜疾病评分均存在显著相关性。使用 ROC 统计,250μg/g 为截断值可指示存在大溃疡,灵敏度为 60.4%,特异性为 79.5%(阳性预测值 [PPV] 78.4%,阴性预测值 [NPV] 62.0%)。CD 中,水平≤250μg/g 预测内镜缓解(CDEIS≤3),灵敏度为 94.1%,特异性为 62.2%(PPV 48.5%,NPV 96.6%)。在 UC 中,粪便钙卫蛋白>250μg/g 对活动性黏膜疾病活动度(Mayo>0)的灵敏度为 71.0%,特异性为 100.0%(PPV 100.0%,NPV 47.1%)。UC 中,钙卫蛋白水平与症状评分显著相关(r=0.561,P<0.001),而在 CD 中则不然。
粪便钙卫蛋白水平与 IBD 的内镜疾病活动度显著相关。该试验在临床实践中可用于评估内镜活动度和缓解情况。